Mid-Market Healthcare: Where Capital Is Going and What It Means for Owners

Healthcare has been one of the most active sectors in private markets over the past eighteen months, for investors and buyers alike. Capital remains available in 2026, but it is more selective, and the businesses attracting it are those that can show their quality in the numbers.

A record year, and a more selective one

Global healthcare private equity reached a record of around $191 billion in deal value in 2025, across roughly 445 buyouts. A handful of very large take-privates drove the headline, but the growth in deal numbers came from below the billion-dollar line, where deals rose 56% by number. That is where mid-market businesses sit. Provider and related services attracted around $62 billion, up 57%.

The first half of 2026 brought more competition for smaller deals. There were 415 funds active in healthcare private equity, up from 331 a year earlier, completing 184 deals against 173, with disclosed value of $51 billion against $61 billion. Healthcare IT is on pace for around 440 deals, ahead of the 2021 record of 424.

The third quarter was quieter. Early figures show deal numbers down by around a quarter on a year earlier, led by physician groups, where longer state reviews have slowed private equity. Strategic and independent buyers have filled part of that gap.

Exits and longer partnerships

Healthcare private equity exits reached around $156 billion in 2025, up from $54 billion in 2024, including more than 150 sponsor-to-sponsor transactions, a record. This year has been more uneven. The number of healthcare IT exits is holding up, but exit value is on pace to fall by around 45%, and many sponsors are using continuation funds to hold assets for longer.

Holding periods tell the same story. The median private equity hold in healthcare services has stretched from 4.7 years in 2021 to 6.6 years in 2025, and 6.1 years for exits through mid-2026. An owner selling to private equity should expect a partnership of six years or more, which puts more weight on fit with the buyer's plan and on management's role within it. A business sold to a sponsor is also increasingly likely to be sold on to another sponsor in time.

Lenders are open, and selective

Direct lenders provided around $24 billion to healthcare in the first half of 2026, making it the second-largest sector within roughly $156 billion of total US direct lending. Lenders are looking for clear repayment visibility, senior security and comfortable headroom on covenants, with direct lending yields of around 7% to 9%.

They are also separating strong credits from weak ones. In the first quarter, refinancing for healthcare borrowers fell from more than $8 billion a year earlier to about $600 million as lenders stepped back from stressed names. Profitable businesses with steady cash flow remain well served.

Specialist equity and family offices

Total capital invested in healthcare stands at around 60% of 2021 levels after many generalist investors left the sector. Those who remain know it well and move with conviction once convinced. They want signed commercial traction, a clear path to profitability, a defined milestone for the new capital and management with real operating depth. A focused process aimed at the right specialists tends to move faster and price better than a broad one aimed at generalists.

Family offices are an important part of the picture. Around 70% make direct investments, and 83% of those deals are co-investments or club deals, with typical direct checks of $1 million to $15 million. Their capital is patient and can be flexible on structure and timing, but they rarely lead cold. The practical route to that capital is usually a well-run process with a credible lead they can follow.

Scale changes the price

In every subsector, the same kind of business commands a higher multiple as it grows.

Moving from the smallest band into the $5 million to $10 million band adds roughly three turns of EBITDA, which is why many owners raise growth capital or make acquisitions before they sell.

Four routes for owners

A profitable mid-market healthcare business has four realistic paths. Minority growth equity brings capital and sector expertise with the owner staying in control, and suits growing businesses with a clear use of funds. Private credit and structured capital provide funding without dilution, with repayment shaped to cash flow, and suit steady, predictable earnings. A partial sale or recapitalization offers liquidity today and a retained stake in future growth. A full sale offers complete liquidity to private equity, a strategic buyer or a family office, and suits owners planning succession or a clean exit.

Each route attracts a different investor, values the business differently and asks something different of the owner, so choosing early shapes how the business is prepared.

Where deals stall

Most stalled processes come down to a gap between the story and the evidence. An ask anchored to an earlier market or to projected growth ends most conversations before diligence begins. "Growth and hiring" reads as no plan, because investors want to see what the money will achieve. Headline numbers must reconcile quickly to statements and contracts, and buyers discount businesses that rely on the founder for every key decision.

Each of these can be addressed before the first investor is approached. In this market, preparation often decides whether a transaction closes on schedule or drifts into next year.